<DOC>
	<DOCNO>NCT01484015</DOCNO>
	<brief_summary>This randomize pilot clinical trial study well give prolong infusion compare standard infusion cefepime hydrochloride work treat patient febrile neutropenia . Giving cefepime hydrochloride long period time may effective give cefepime hydrochloride standard time .</brief_summary>
	<brief_title>Prolonged Standard Infusion Cefepime Hydrochloride Treating Patients With Febrile Neutropenia</brief_title>
	<detailed_description>OBJECTIVES : I . The objective study describe outcomes associate prolonged infusion ( 3 hour ) compare standard infusion ( 30 minute ) cefepime ( cefepime hydrochloride ) among patient treat empirically febrile neutropenia . OUTLINE : Patients randomize 1 2 treatment arm . All patient receive cefepime hydrochloride intravenously ( IV ) 30 minute first dose . ARM I : Patients receive cefepime hydrochloride intravenously ( IV ) 30 minute . ARM II : Patients receive cefepime hydrochloride IV 3 hour . Treatment repeat every 8 hour .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Germinoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic , Atypical , BCR-ABL Negative</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Leukemia , Neutrophilic , Chronic</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<mesh_term>Trophoblastic Neoplasms</mesh_term>
	<mesh_term>Gestational Trophoblastic Disease</mesh_term>
	<mesh_term>Cefepime</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<criteria>Absolute neutrophil count &lt; 500 cells/mm^3 &lt; 1000 cells/mm^3 predict decrease &lt; 500 cells/mm^3 Temperature &gt; 38.0 degree Celsius Received chemotherapy stemcell transplant treatment malignancy myelodysplastic syndrome ( MDS ) Cefepime prescribe dose 2 gram IV every 8 hour Allergy cephalosporin antibiotic Estimated creatinine clearance &lt; 50 milliliters/minute Concurrent antigram negative antimicrobial Diagnostic criterion suggestive sepsis Circumstances may make 3 hour infusion impractical Solid tumor malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>